Search results
Jul 21, 2011 · Under the terms of the agreement, Bristol-Myers Squibb will acquire all of Amira Pharmaceuticals’ issued and outstanding shares of capital stock and stock equivalents in an all-cash transaction ...
Sep 9, 2011 · This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, relating to the acquisition of Amira Pharmaceuticals, Inc ...
Oct 28, 2010 · SAN DIEGO, Oct. 28 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 clinical study with AM152, a novel LPA1 antagonist, in normal, healthy subjects. "We are excited to begin our journey exploring the therapeutic value of AM152, a potentially novel anti-fibrotic agent.
Amira Pharmaceuticals | 3,263 followers on LinkedIn. Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat ...
Jul 22, 2011 · 22.07.2011 -. Bristol-Myers Squibb said Thursday it has agreed to acquire Amira Pharmaceuticals, a privately held company, for an upfront payment of $325 million in cash. The terms also include a potential additional milestone payments totaling $150 million. The closing of the transaction is subject to customary regulatory approvals. Amira, a ...
Jul 21, 2011 · Bristol-Myers Squibb Company (NYSE:BMY) and Amira Pharmaceuticals, Inc., announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire privately held Amira Pharmaceuticals, a small-molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.
People also ask
What is Amira Pharmaceuticals?
Will Bristol-Myers Squibb buy Amira Pharmaceuticals?
Who was Amira Pharmaceuticals' financial advisor?
What is Amira Medical Health Services Ltd?
Aug 15, 2011 · This is down from $1.35 billion, or $1.22 per share, at the same time last year. However, the company reports that revenues rose to $6.25 billion, a 9% increase. Bristol-Myers Squibb has agreed to ...
